Revicki D A, Luce B R
Medical Technology Assessment and Policy Research Program, Battelle Centers for Public Health Research and Evaluation, Arlington, VA 22201, USA.
Psychopharmacol Bull. 1995;31(1):57-65.
There is concern in developed countries about the increasing cost of health care. Developers of new psychopharmacologic agents are asked to demonstrate cost-effectiveness as well as safety and efficacy before widespread use is encouraged. Pharmacoeconomic studies are designed to evaluate the health outcomes and cost-effectiveness of new medical treatments relative to existing treatments. Retrospective and prospective research designs have been used in pharmacoeconomic studies. New approaches such as medical effectiveness studies and modeling studies based on clinical decision analysis are increasingly used to evaluate cost-effectiveness. This article introduces important concepts of pharmacoeconomic evaluation and discusses the methods and their strengths and weaknesses. Safety and efficacy studies and pharmacoeconomic studies provide useful and complementary evidence on how a new treatment affects clinical, health-related quality-of-life, and economic outcomes.
发达国家对医疗保健费用的不断上涨表示担忧。新型精神药物的开发者在被鼓励广泛使用之前，需要证明其成本效益以及安全性和有效性。药物经济学研究旨在评估新医疗疗法相对于现有疗法的健康结果和成本效益。回顾性和前瞻性研究设计已被用于药物经济学研究。诸如基于临床决策分析的医学有效性研究和建模研究等新方法越来越多地用于评估成本效益。本文介绍了药物经济学评估的重要概念，并讨论了其方法及其优缺点。安全性和有效性研究以及药物经济学研究为新疗法如何影响临床、健康相关生活质量和经济结果提供了有用且互补的证据。
